ScreenerHero

ALDXAldeyra Therapeutics, Inc.

NAS · US · Healthcare · Biotechnology · aldeyra.com
1.520USD-3.80%Mkt Cap: 91.70M $P/E: —

Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated diseases. Its lead product candidate is reproxalap, a reactive aldehyde species (RASP) modulator, wh…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$138.82BUSDP/E 31.9
REGN
Regeneron Pharmaceuticals, Inc.
$85.87BUSDP/E 20.5
ARGX
ARGENX SE
$61.34BUSDP/E 39.8
ARGX
argenx SE
$65.05BUSDP/E 39.6
MRNA
Moderna, Inc.
$57.94BUSD
UCB
UCB SA
$45.95BUSDP/E 19.6
RVMD
Revolution Medicines, Inc.
$44.89BUSD
ONC
BeOne Medicines AG
$42.36BUSDP/E 67.2
RPRX
Royalty Pharma Plc Class A
$35.43BUSDP/E 32.6
ALNY
Alnylam Pharmaceuticals, Inc.
$31.61BUSDP/E 41.2
BNTX
BioNTech SE
$29.28BUSD
INSM
Insmed Incorporated
$27.47BUSD
ROIV
Roivant Sciences Ltd. Common Shares
$26.22BUSD
INCY
Incyte Corporation
$25.91BUSDP/E 16.2
GMAB
Genmab A/S
$20.86BUSDP/E 26.3
GMAB
Genmab A/S
$19.26BUSDP/E 26.6
ASND
Ascendis Pharma A/S
$16.61BUSDP/E 19.6
JAZZ
Jazz Pharmaceuticals plc
$16.51BUSDP/E 17.4
BBIO
BridgeBio Pharma, Inc.
$15.93BUSD
EXEL
Exelixis, Inc.
$13.40BUSDP/E 17.0

Key Statistics

Company
Market Cap91.70M $
Enterprise Value45.54M $
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-33.85M $
Revenue/Share—
Last Price1.520 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees6
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINUS01438T1060
Valuation
P/E (Trailing)—
P/E (Forward)-5.45
PEG—
EV/EBITDA-1.91
EV/Revenue—
P/S—
P/B2.39
EPS (TTM)-0.36
EPS (Forward)-0.28
52W Range
1.0709% of range6.175
52W High6.175 USD
52W Low1.070 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-76.49%
ROA-46.97%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-33.35M $
CapEx (TTM)—
FCF Margin—
FCF Yield-17.03%
Net Debt-44.95M $
Net Debt/EBITDA1.89
Balance Sheet
Debt/Equity0.35
Current Ratio4.91
Quick Ratio4.67
Book Value/Sh0.6280 USD
Cash/Share0.7470 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div Date—
Pay Date—
Analyst Consensus
Rating1.5 (Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)6.600 USD
Upside (mean)+334.2%
Target Range2.000 USD – 13.00 USD
$2.000+334.2% to mean$13.00
# Analysts5
Ownership
Shares Out.60.33M
Float48.95M
Insiders3.60%
Institutions61.62%
Short Interest
Short Ratio2.3d
Short % Float5.86%
Short % Out.5.68%
Shares Short3.42M
Short (prev mo.)5.68M
Technical
SMA 501.777 (-14.5%)
SMA 2003.211 (-52.7%)
Beta1.20
S&P 52W Chg18.16%
Avg Vol (30d)1.05M
Avg Vol (10d)905.78K
Technical Indicators
RSI (14)41.8
MACD-0.0682
MACD Signal-0.0803
MACD Hist.+0.0121
BB Upper1.632 USD
BB Middle1.550 USD
BB Lower1.468 USD
BB Width10.58%
ATR (14)0.1043 USD
Vol Ratio (20d)1.21x